[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-327187-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-327187-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cxcr4-targeted-theranostics-in-hematooncology-opportunities-and-challenges","CXCR4-targeted Theranostics in Hematooncology - Opportunities and Challenges","","C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed across many cancers, including hematopoietic malignancies, enabling a theranostic strategy that first visualizes CXCR4 expression in vivo and then uses CXCR4-targeted radioligand therapy (RLT) for combined anti-cancer and myeloablative effects. An opinion article summarizes expert statements from a hemato-oncology and nuclear medicine meeting, concluding benefits for marginal zone lymphoma imaging, RLT efficacy in advanced treatment-refractory T-cell lymphomas, and the need for prospective CXCR4-based trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cxcr4-targeted-theranostics-in-hematooncology-opportunities-and-challenges/327187/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cxcr4-targeted-theranostics-in-hematooncology-opportunities-and-challenges/327187.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes CXCR4 suitable for theranostic approaches in hematologic cancers?","Question",{"text":63,"@type":64},"CXCR4 is overexpressed in multiple cancers, including neoplasms of hematopoietic origin, allowing molecular imaging to read out CXCR4 expression in vivo and enabling CXCR4-targeted radioligand therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How could CXCR4-directed PET/CT help patients with marginal zone lymphoma?",{"text":68,"@type":64},"The expert panel concludes that CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence-based needs are highlighted for future clinical use of CXCR4 theranostics?",{"text":72,"@type":64},"The article states that prospective trials with CXCR4-based imaging and theranostics are warranted.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},327187,1790015069,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article published online: 2024-01-08  \nOriginal Article  \nCXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges  \nCXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen  \nAuthors  \nRudolf Werner1, Alexander Haug2, Christian Buske3, Simon Heidegger4, Anna L. Illert5, Florian Bassermann4, Peter Herhaus4, Andreas Buck1, Johannes Duell6, Max S Topp6, Sabrina Kraus6, Hermann Einsele6, Constantin Lapa7, Markus Raderer8, Georg Lenz9, Stefan Habringer10, Bastian von Tresckow11, Ulrich Keller10  \nAffiliations  \n1 Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany  \n2 Clinical Department of Nuclear Medicine , University Hospital AKH Vienna, Wien, Austria  \n3 Institute of Experimental Cancer Research, Ulm University Hospital, Ulm, Germany  \n4 Department of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany  \n5 Department of Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany  \n6 Internal Medicine II, University Hospital Würzburg, Würzburg, Germany  \n7 Nuclear Medicine, Faculty of Medicine , University of Augsburg, Augsburg, Germany  \n8 Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria  \n9 Department of Medicine A-Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany  \n10 Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany  \n11 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany  \nKey words  \nCXCR4, chemokine receptor, theranostics, marginal zone lymphoma, T-cell lymphoma, [68Ga]Ga-PentixaFor  \nreceived 09.08.2023 accepted 18.09.2023 published online 08.01.2024  \nBibliography  \nNuklearmedizin 2024; 63: 57–61  \nDOI 10.1055/a-2194-9965  \nISSN 0029-5566  \n© 2024. The Author(s) .  \nThis is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/)).  \nGeorg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany  \nCorrespondence Dr. Rudolf Werner  \nDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany  \n[werner_r1@ukw.de](werner_r1@ukw.de)  \nABSTRACT  \nC-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.  \nWerner R et al. CXCR4-targeted Theranostics in… Nuklearmedizin 2024; 63: 57–61 | © 2024. The Author(s) . 57  \n▶ Fig. 1 Maximum intensity projections of PET/CTs using [18F]FDG (leftmost panels) and [68Ga]Ga-PentixaFor (rightmost panels) in a subject with orbital marginal zone lymphoma. The middle panels show PET/CT images of axial sections of lymphoma manifestation using [18F]FDG (bottom) and [68Ga]Ga-PentixaFor (top) . On [18F]FDG, MZL manifestation is not visib","cbCaihPaot07A8QP","https://ap.wps.com/l/cbCaihPaot07A8QP","pdf",437191,"English","# Abstract\n# Introduction\n# Expert panel statement I: CXCR4-directed molecular imaging may be useful for marginal zone lymphoma patients\n## CXCR4-directed Molecular Imaging","[{\"question\":\"What makes CXCR4 suitable for theranostic approaches in hematologic cancers?\",\"answer\":\"CXCR4 is overexpressed in multiple cancers, including neoplasms of hematopoietic origin, allowing molecular imaging to read out CXCR4 expression in vivo and enabling CXCR4-targeted radioligand therapy.\"},{\"question\":\"How could CXCR4-directed PET/CT help patients with marginal zone lymphoma?\",\"answer\":\"The expert panel concludes that CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma.\"},{\"question\":\"What evidence-based needs are highlighted for future clinical use of CXCR4 theranostics?\",\"answer\":\"The article states that prospective trials with CXCR4-based imaging and theranostics are warranted.\"}]","CXCR4-targeted Theranostics in Hematooncology - Opportunities and Challenges | PDF",1789976636,13]